- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00854919
Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder (OCDDRUG)
An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant obsessive-compulsive disorder (OCD) in short terms trials, there are few data on the effectiveness and safety of these agents in clinical settings over the long term.
Method: Subjects (n=46) who responded to selective SRIs (SSRIs) in an initial 12-week trial were continued on SRI-monotherapy plus cognitive-behavioral therapy (CBT) for one year. Subjects (n=44) who failed to respond to SSRIs were randomly assigned to one of 3 AAPDs such as risperidone and were consecutively treated using SSRI+AAPD combined with CBT for a year.
Study Overview
Status
Intervention / Treatment
Detailed Description
More recently, second-generation atypical antipsychotic drugs (AAPD) that modulate both 5-HT and DA function, such as risperidone (RIS), olanzapine (OLZ) and quetiapine (QET), have been found effective in the augmentation of SSRIs for treatment-resistant OCD.
Nevertheless, the AAPDs have been associated with common and serious adverse effects, such as body weight (BW) gain and metabolic dysregulation. Metabolic dysregulation includes glucoregulatory dysfunction and dyslipidemia. Indeed, studies of some AAPD in SSRI-refractory OCD patients have similarly reported significant BW gain. AAPD-induced BW gain may influence patients' adherence to medication and places them at risk for a broad range of medical problems.
Most work on AAPDs in treatment-refractory OCD has been conducted in the form of short-term efficacy studies. There have been fewer studies of the effectiveness, safety, and tolerability of these agents in the context of a clinic where CBT is also provided, and where treatment is continued for a significant period of time. In the current effectiveness study, we sought to examine the response of SSRI-refractory patients to augmentation with AAPDs, comparing adverse events in such compared to a control group of SSRI responders.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Osaka, Japan, 545-8585
- Dept of Neuropsychiatry, Osaka City University, graduate School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18 years of age or over
- Patients were diagnosed as having obsessive-compulsive disorder by the Structured Clinical Interview for DSM-IV Patient version (SCID-P)
- They received standardized treatment for at least 1 year at the OCD clinic in our university hospital.
- Each subject gave written informed consent to take part after receiving a complete description of this study.
- All subjects were free of medical illness based on results of physical examination and screening tests of blood and urine, and no subjects received any lipid lowering or hypoglycemic agent during the 1-year study period.
Exclusion Criteria:
- Current clinically significant medical conditions such as diabetes
Study Plan
How is the study designed?
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CBT
All subjects received cognitive-behavioral therapy (CBT) during the study period.
|
After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
|
EXPERIMENTAL: 1
Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
|
After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day)
was added on ongoing SSRI(Paroxetine, Fluvoxamine).
|
ACTIVE_COMPARATOR: 2
Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
|
After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day)
was added on ongoing SSRI(Paroxetine, Fluvoxamine).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Yale-Brown Obsessive-Compulsive Scale
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
yale-Brown Obsessive-Compulsive Scale
Time Frame: 1 year
|
1 year
|
BMI, TG, T-CHO, FBS
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18591305
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SSRI-Refractory Obsessive-Compulsive Disorder
-
Novartis PharmaceuticalsTerminatedPatient Diagnosed With OCD and Resistant to SSRI Treatment | Failed SSRI Over 12 Weeks at Appropriate DosesGermany, Switzerland, Bulgaria, United States, Czech Republic
-
InSightecCompletedMedication-refractory Obsessive Compulsive Disorder (OCD)Korea, Republic of
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
Clinical Trials on exposure response prevention
-
Karolinska InstitutetCompletedIllness Anxiety Disorder | Somatic Symptom Disorder | Severe Health AnxietySweden
-
Karolinska InstitutetCompletedIllness Anxiety Disorder | Somatic Symptom Disorder | Severe Health AnxietySweden
-
NOCDCompletedObsessive-Compulsive DisorderUnited States
-
New York State Psychiatric InstituteCompletedObsessive-Compulsive DisorderUnited States
-
Ruijin HospitalWest China Hospital; First Affiliated Hospital of Xinjiang Medical University; Shanghai Hongkou Mental Health Center and other collaboratorsUnknownObsessive-Compulsive DisorderChina
-
Concordia University, MontrealUniversity of British Columbia; University College London Hospitals; McGill University and other collaboratorsRecruitingObsessive-Compulsive DisorderCanada
-
University of California, Los AngelesVirtually Better, Inc.CompletedObsessive-Compulsive DisorderUnited States
-
Massachusetts General HospitalCompletedObsessive Compulsive DisorderUnited States
-
Norwegian University of Science and TechnologyNorwegian Foundation for Health and RehabilitationCompletedObsessive-Compulsive DisorderNorway
-
Columbia UniversityInternational OCD FoundationRecruiting